EN | UA
EN | UA

Help Support

Back

Safety and efficacy of secukinumab in pediatrics with psoriasis

Safety and efficacy of secukinumab in pediatrics with psoriasis Safety and efficacy of secukinumab in pediatrics with psoriasis
Safety and efficacy of secukinumab in pediatrics with psoriasis Safety and efficacy of secukinumab in pediatrics with psoriasis

This study explored the efficacy and safety of 2 dosage regimens of secukinumab for the management of psoriasis in pediatrics.

See All

Key take away

In pediatrics (aged 6-<18-years) having moderate-to-severe plaque psoriasis, the dosing regimens of secukinumab were efficacious and well-tolerated. 

Background

This study explored the efficacy and safety of 2 dosage regimens of secukinumab for the management of psoriasis in pediatrics.

Method

In this randomized, phase-III, open-label, multicenter-study, two dosage regimens of secukinumab were used: (i) low dose: 75/75/150 mg and (ii) high dose: 75/150/300 mg. The dosage regimens were stratified and randomized by the severity of disease (severe, moderate) and weight (<25kg, 25-<50kg, ≥50kg).

Estimation of Psoriasis Area and Severity Index  (PASI) 75/90 and Investigator's Global Assessment (IGA) 0/1 was done.

Result

Regarding PASI 75/90 and IGA0/1 responses, both high and low doses of secukinumab showed superiority to historical placebo at week 12. The estimated probability of positive therapeutic impact for secukinumab low dose or high dose in comparison with the historical placebo is 1 (i.e. 100%). For low and high doses, the IGA0/1 response-rates, PASI90 response-rates, and PASI75 response-rates at Week-12 are shown in Table 1:


Conclusion

Secukinumab showed high efficacy and favorable safety profile with both high and low dosing regimens up to 24 weeks in pediatrics suffering from psoriasis. 

Source:

Journal of the American Academy of Dermatology

Article:

A phase III open-label, randomized multicenter study to evaluate efficacy and safety of secukinumab in pediatric patients with moderate to severe plaque psoriasis: 24-week results

Authors:

Nina Magnolo et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru ua
Try: